ArticleIrish journal of medical science2013
Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre.
Article in Irish journal of medical science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pooled it
- Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.World journal of gastroenterology · 2015Trial
- High Levels ofMicroorganisms · 2026Article
- Levofloxacin+Tetracycline Quadruple Regimen for Eradication ofMiddle East journal of digestive diseases · 2023Article
- Rifabutin for the Treatment ofPathogens (Basel, Switzerland) · 2020Review
- Reevaluation of the Efficacy of First Line Regimen forClinical and experimental gastroenterology · 2020Article
- Can bacterial virulence factors predict antibiotic resistantWorld journal of gastroenterology · 2018Article
- Loop-Mediated Isothermal Amplification as a Fast Noninvasive Method of Helicobacter pylori Diagnosis.Journal of clinical laboratory analysis · 2016Article
- Antibiotic treatment for Helicobacter pylori: Is the end coming?World journal of gastrointestinal pharmacology and therapeutics · 2015Review
- Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.World journal of methodology · 2015Review
- Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis.Gastroenterology research and practice · 2015Review
- Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance.World journal of gastroenterology · 2014Review
- Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.World journal of gastroenterology · 2014Review
- Fluoroquinolone-based protocols for eradication of Helicobacter pylori.World journal of gastroenterology · 2014Review
- How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?World journal of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHelicobacter pylori eradication rates using conventional triple therapies are falling, making viable second-line and rescue regimens necessary. Levofloxacin, tetracycline and rifabutin are three efficacious antibiotics for rescue therapy.
aimWe aimed to assess the resistance rates for H. pylori against these antibiotics in an Irish cohort.
methodsGastric biopsies were collected from 85 patients infected with H. pylori (mean age 46 years) in the Adelaide and Meath Hospital, Dublin in 2008 and 2009. Susceptibility to antibiotics was tested using the Etest. Clinical information was obtained from endoscopy reports and chart review.
results50.6 % of patients were females. Mean age was 47 years. Ten had prior attempts at eradication therapy with amoxicillin-clarithromycin-PPI, two had levofloxacin-based second-line therapy. 11.7 % [95 % CI (6.5-20.3 %)] (N = 10) had strains resistant to levofloxacin. There were no strains resistant to rifabutin or tetracycline. Levofloxacin resistance in the under 45 age group was 2.6 % (1/38) compared to 19.1 % (9/47) of above 45 age group (p = 0.02). DISCUSSION: The levofloxacin rates illustrated in this study are relatively low by European standards and in line with other studies from the United Kingdom and Germany, with younger patients having very low levels of resistance. Levofloxacin, tetracycline and rifabutin are all valid options for H. pylori eradication in Irish patients but the importance of compliance cannot be underestimated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.